Corcept Therapeutics Inc (CORT) shareholders
Close on Nov 13, 2026Market cap $7.88BP/E 173.7Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 9,614,217 | 8.90% | 13G (passive) amendment | Sep 30, 2026 |
| Ingalls & Snyder LLC | 7,263,466 | 6.80% | 13G (passive) amendment | Dec 31, 2025 |
| Joseph K. Belanoff | 6,822,335 | 6.30% | 13G (passive) amendment | Dec 31, 2024 |
| Renaissance Technologies Holdings Corporation Joint filing with Renaissance Technologies LLC (5.47%) | 5,758,528 | 5.47% | 13G (passive) amendment | Dec 31, 2025 |
| G. Leonard Baker, Jr. | 5,512,696 | 5.30% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CORT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12,432,023 | 11.50% | $1.08B | +280,747 | 0.02% |
| Ingalls & Snyder LLC | 7,934,507 | 7.34% | $689.91M | +325,791 | 18.83% |
| Renaissance Technologies LLC | 5,261,628 | 4.87% | $457.50M | −421,155 | 0.63% |
| Vanguard Portfolio Management LLC | 5,044,638 | 4.67% | $438.63M | +224,070 | 0.02% |
| Vanguard Capital Management LLC | 4,172,482 | 3.86% | $362.80M | +95,286 | 0.01% |
| Parallel Advisors, LLC | 3,962,177 | 3.67% | $344.51M | −15,227 | 5.25% |
| FMR LLC | 3,337,618 | 3.09% | $290.21M | +147,426 | 0.01% |
| State Street Corp | 3,279,381 | 3.03% | $285.15M | +78,435 | 0.01% |
| Aqr Capital Management LLC | 2,582,561 | 2.39% | $224.55M | +2,176,356 | 0.08% |
| Geode Capital Management, LLC | 2,532,198 | 2.34% | $220.21M | −181,321 | 0.01% |
| First Trust Advisors LP | 1,829,545 | 1.69% | $159.08M | −343,831 | 0.09% |
| Tang Capital Management LLC | 1,500,000 | 1.39% | $130.43M | – | 5.92% |
| UBS Group AG | 1,377,658 | 1.27% | $119.79M | +13,990 | 0.02% |
| Dimensional Fund Advisors LP | 1,318,821 | 1.22% | $114.68M | −234,314 | 0.02% |
| Charles Schwab Investment Management Inc | 1,157,580 | 1.07% | $100.65M | +37,621 | 0.01% |
| Morgan Stanley | 1,137,559 | 1.05% | $98.91M | +118,714 | 0.01% |
| D. E. Shaw & Co., Inc. | 883,001 | 0.82% | $76.78M | −298,347 | 0.04% |
| Cerity Partners LLC | 797,119 | 0.74% | $69.31M | +65,430 | 0.08% |
| Mpm Bioimpact LLC | 771,028 | 0.71% | $67.04M | −214,672 | 4.09% |
| Northern Trust Corp | 753,796 | 0.70% | $65.54M | +110,638 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 422 | 82M | 76.2% | 129 / 146 | 109 / 54 | 11M | 7M |
| Q1 2026 | 352 | 80M | 73.6% | 69 / 114 | 128 / 101 | 24M | 12M |
| Q4 2025 | 390 | 77M | 70.9% | 62 / 120 | 157 / 94 | 7M | 9M |
| Q3 2025 | 429 | 78M | 72.2% | 62 / 145 | 157 / 50 | 7M | 8M |
| Q2 2025 | 422 | 79M | 73.2% | 71 / 155 | 157 / 65 | 8M | 12M |
| Q1 2025 | 422 | 83M | 77.2% | 104 / 126 | 146 / 41 | 6M | 7M |
| Q4 2024 | 367 | 84M | 78.1% | 81 / 116 | 124 / 30 | 4M | 8M |
| Q3 2024 | 321 | 89M | 82.1% | 64 / 106 | 106 / 27 | 21M | 5M |
| Q2 2024 | 286 | 90M | 82.8% | 37 / 104 | 114 / 33 | 3M | 11M |
| Q1 2024 | 285 | 97M | 89.8% | 54 / 110 | 89 / 40 | 16M | 5M |
| Q4 2023 | 273 | 86M | 79.8% | 56 / 82 | 93 / 26 | 8M | 4M |
| Q3 2023 | 246 | 83M | 76.3% | 40 / 82 | 92 / 16 | 6M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
304 funds held CORT in Q2 2026, 69% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CORT | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 5,753,834 | 5.32% | $500.30M | 0.45% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,893,842 | 2.68% | $251.62M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,093,441 | 1.94% | $182.02M | 0.10% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 1,810,937 | 1.68% | $157.46M | 5.60% | Jun 30, 2026 |
| Fidelity Contrafund | 1,317,529 | 1.22% | $114.56M | 0.06% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,205,900 | 1.12% | $104.85M | 0.22% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,095,943 | 1.01% | $95.29M | 0.10% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 876,533 | 0.81% | $76.21M | 0.45% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 858,583 | 0.79% | $74.65M | 0.91% | Jun 30, 2026 |
| Vanguard Tax-Managed Small-Cap Fund | 615,785 | 0.57% | $53.54M | 0.47% | Jun 30, 2026 |
| iShares Russell Mid-Cap Growth ETF | 560,117 | 0.52% | $48.70M | 0.23% | Jun 30, 2026 |
| State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF | 542,620 | 0.50% | $47.18M | 0.91% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 506,746 | 0.47% | $35.21M | 0.67% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 480,572 | 0.44% | $33.39M | 0.08% | May 31, 2026 |
| Fullerthaler Behavioral Small-Cap Growth | 470,000 | 0.43% | $40.87M | 0.66% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joseph K. Belanoff | Chief Executive Officer, Director | 3,415,489 | 3.16% | Jun 2, 2026 |
| Roberto Wandenkolk Vieira | President, Oncology | 3,946 | 0.00% | Nov 4, 2026 |
| Justin Frederick Gunn | See Remarks | 12,191 | 0.01% | Oct 5, 2026 |
| Joseph Douglas Lyon | See Remarks | 5,683 | 0.01% | Oct 5, 2026 |
| Gary Charles Robb | Chief Business Officer | 94,914 | 0.09% | Sep 28, 2026 |
| Atabak Mokari | Chief Financial Officer | 16,304 | 0.02% | Sep 3, 2026 |
| William Guyer | Chief Development Officer | 10,387 | 0.01% | Sep 3, 2026 |
| Hazel Hunt | Chief Scientific Officer | 255,437 | 0.24% | Mar 3, 2026 |
| Daniel N. Swisher JR | Director | 0 | – | Nov 13, 2026 |
| James N. Wilson | Director | 1,543,907 | 1.43% | Oct 16, 2026 |
| Kimberly Park | Director | 0 | – | Aug 28, 2026 |
| David L. Mahoney | Director | 1,282,839 | 1.19% | Aug 20, 2026 |
| G. Leonard Baker Jr | Director | 5,525,978 | 5.11% | May 26, 2026 |
| Gregg H. Alton | Director | – | – | May 26, 2026 |
| Joshua M. Murray | Director | – | – | May 26, 2026 |
| Gillian Cannon | Director | 0 | – | Sep 11, 2025 |
| Sean Maduck | – | 18,938 | 0.02% | Nov 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Daniel N. Swisher JR Director | Nov 10, 2026 | Sale(10b5-1 plan) | −1,500 | $74.07 | $111.10K | 0 |
| Daniel N. Swisher JR Director | Nov 10, 2026 | Option exercise | +400 | $10.50 | $4.20K | 1,500 |
| Daniel N. Swisher JR Director | Nov 10, 2026 | Option exercise | +1,100 | $14.08 | $15.49K | 1,100 |
| Sean Maduck – | Nov 3, 2026 | Sale(10b5-1 plan) | −4,542 | $82.68 | $375.51K | 9,938 |
| Sean Maduck – | Nov 3, 2026 | Sale(10b5-1 plan) | −8,617 | $82.02 | $706.76K | 14,480 |
| Sean Maduck – | Nov 3, 2026 | Option exercise | +13,159 | $8.27 | $108.82K | 23,097 |
| Sean Maduck – | Nov 2, 2026 | Sale(10b5-1 plan) | −11,841 | $81.42 | $964.07K | 9,938 |
| Sean Maduck – | Nov 2, 2026 | Option exercise | +11,841 | $8.27 | $97.93K | 21,779 |
| Roberto Wandenkolk Vieira President, Oncology | Nov 2, 2026 | Sale(10b5-1 plan) | −1,676 | $81.52 | $136.63K | 3,946 |
| Roberto Wandenkolk Vieira President, Oncology | Nov 2, 2026 | Sale(10b5-1 plan) | −6,657 | $80.73 | $537.44K | 5,622 |
| Roberto Wandenkolk Vieira President, Oncology | Nov 2, 2026 | Option exercise | +8,333 | $21.63 | $180.24K | 12,279 |
| James N. Wilson Director | Oct 15, 2026 | Sale(10b5-1 plan) | −300 | $116.30 | $34.89K | 1,054,543 |
| James N. Wilson Director | Oct 15, 2026 | Sale(10b5-1 plan) | −3,046 | $115.39 | $351.48K | 1,054,843 |
| James N. Wilson Director | Oct 15, 2026 | Sale(10b5-1 plan) | −6,654 | $114.48 | $761.72K | 1,057,889 |
| Roberto Wandenkolk Vieira President, Oncology | Oct 2, 2026 | Sale(10b5-1 plan) | −5,147 | $116.58 | $600.06K | 3,946 |
| Roberto Wandenkolk Vieira President, Oncology | Oct 2, 2026 | Sale(10b5-1 plan) | −2,086 | $115.73 | $241.41K | 9,093 |
| Roberto Wandenkolk Vieira President, Oncology | Oct 2, 2026 | Sale(10b5-1 plan) | −1,100 | $114.52 | $125.97K | 11,179 |
| Roberto Wandenkolk Vieira President, Oncology | Oct 2, 2026 | Option exercise | +8,333 | $21.63 | $180.24K | 12,279 |
| Joseph Douglas Lyon See Remarks | Oct 2, 2026 | Sale(10b5-1 plan) | −4,744 | $116.54 | $552.87K | 5,683 |
| Joseph Douglas Lyon See Remarks | Oct 2, 2026 | Sale(10b5-1 plan) | −4,446 | $115.70 | $514.39K | 10,427 |
| Joseph Douglas Lyon See Remarks | Oct 2, 2026 | Option exercise | +5,833 | $19.26 | $112.34K | 14,873 |
| Joseph Douglas Lyon See Remarks | Oct 2, 2026 | Option exercise | +3,357 | $13.56 | $45.52K | 9,040 |
| Sean Maduck See Remarks | Oct 2, 2026 | Sale(10b5-1 plan) | −8,744 | $116.55 | $1.02M | 9,938 |
| Sean Maduck See Remarks | Oct 2, 2026 | Sale(10b5-1 plan) | −15,843 | $116.12 | $1.84M | 18,682 |
| Sean Maduck See Remarks | Oct 2, 2026 | Option exercise | +24,587 | $8.27 | $203.33K | 34,525 |
| Joseph Douglas Lyon See Remarks | Oct 1, 2026 | Sale(10b5-1 plan) | −810 | $115.40 | $93.47K | 5,683 |
| Joseph Douglas Lyon See Remarks | Oct 1, 2026 | Option exercise | +810 | $13.56 | $10.98K | 6,493 |
| Sean Maduck See Remarks | Oct 1, 2026 | Sale(10b5-1 plan) | −413 | $115.54 | $47.72K | 9,938 |
| Sean Maduck See Remarks | Oct 1, 2026 | Option exercise | +413 | $8.27 | $3.42K | 10,351 |
| Gary Charles Robb Chief Business Officer | Sep 24, 2026 | Gift | −17,100 | – | – | 14,056 |
| Gary Charles Robb Chief Business Officer | Sep 24, 2026 | Gift | +5,000 | – | – | 20,571 |
| Gary Charles Robb Chief Business Officer | Sep 24, 2026 | Gift | +5,000 | – | – | 20,571 |
| Gary Charles Robb Chief Business Officer | Sep 17, 2026 | Option exercise | +17,493 | $8.27 | $144.67K | 31,156 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 16, 2026 | Sale(10b5-1 plan) | −296 | $100.82 | $29.84K | 3,946 |
| James N. Wilson Director | Sep 15, 2026 | Sale(10b5-1 plan) | −6,800 | $110.27 | $749.84K | 1,067,743 |
| James N. Wilson Director | Sep 15, 2026 | Sale(10b5-1 plan) | −400 | $110.84 | $44.34K | 1,067,343 |
| James N. Wilson Director | Sep 15, 2026 | Sale(10b5-1 plan) | −2,800 | $111.70 | $312.76K | 1,064,543 |
| Joseph Douglas Lyon See Remarks | Sep 14, 2026 | Sale(10b5-1 plan) | −2,188 | $114.12 | $249.69K | 5,683 |
| Joseph Douglas Lyon See Remarks | Sep 14, 2026 | Option exercise | +7,404 | $13.56 | $100.40K | 15,683 |
| Joseph Douglas Lyon See Remarks | Sep 14, 2026 | Sale(10b5-1 plan) | −7,812 | $113.32 | $885.26K | 7,871 |
| Joseph Douglas Lyon See Remarks | Sep 14, 2026 | Option exercise | +2,596 | $11.35 | $29.46K | 8,279 |
| Gary Charles Robb Chief Business Officer | Sep 2, 2026 | Tax withholding | −91 | $113.38 | $10.32K | 13,663 |
| Joseph Douglas Lyon See Remarks | Sep 2, 2026 | Tax withholding | −72 | $113.38 | $8.16K | 5,683 |
| Sean Maduck See Remarks | Sep 2, 2026 | Tax withholding | −117 | $113.38 | $13.27K | 9,938 |
| Atabak Mokari Chief Financial Officer | Sep 2, 2026 | Tax withholding | −102 | $113.38 | $11.56K | 16,304 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −974 | $112.40 | $109.48K | 12,694 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Tax withholding | −102 | $113.38 | $11.56K | 4,242 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Option exercise | +58,333 | $21.63 | $1.26M | 62,575 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −23,600 | $109.35 | $2.58M | 38,975 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −23,770 | $110.70 | $2.63M | 15,205 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −1,537 | $111.37 | $171.18K | 13,668 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −1,606 | $113.72 | $182.63K | 11,088 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −5,621 | $114.58 | $644.05K | 5,467 |
| Roberto Wandenkolk Vieira President, Oncology | Sep 2, 2026 | Sale(10b5-1 plan) | −1,225 | $115.44 | $141.41K | 4,242 |
| Gary Charles Robb Chief Business Officer | Sep 1, 2026 | Award | +164 | – | – | 13,754 |
| Gary Charles Robb Chief Business Officer | Sep 1, 2026 | Award | +164 | $113.38 | $18.59K | 13,590 |
| Joseph Douglas Lyon See Remarks | Sep 1, 2026 | Award | +130 | $113.38 | $14.74K | 5,625 |
| Joseph Douglas Lyon See Remarks | Sep 1, 2026 | Award | +130 | – | – | 5,755 |
| Sean Maduck See Remarks | Sep 1, 2026 | Award | +150 | – | – | 10,055 |
| Sean Maduck See Remarks | Sep 1, 2026 | Option exercise | +25,000 | $8.27 | $206.75K | 34,755 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Corcept Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 31,077 shares on Sep 3, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Daniel N. Swisher JR Director | Nov 10, 2026 | 1,500 | $112.54K | Nov 10, 2026 | Exercise of Stock Options |
| Joseph Douglas Lyon Officer | Oct 1, 2026 | 10,000 | $1.15M | Oct 1, 2026 | stock option exercise |
| James N. Wilson Director | Sep 15, 2026 | 30,000 | $3.34M | Sep 15, 2026 | STOCK OPTION AWARDS |
| Joseph Douglas Lyon Officer | Sep 14, 2026 | 10,000 | $1.13M | Sep 14, 2026 | Stock Option Exercise |
| Roberto Wandenkolk Vieira Officer | Sep 2, 2026 | 75,295 | $8.34M | Sep 2, 2026 | Stock Option Exercise |
| Kimberly Park Director | Aug 26, 2026 | 26,685 | $3.27M | Aug 26, 2026 | Stock Option Exercise |
| Sean Maduck Officer | Aug 25, 2026 | 175,000 | $21.98M | Aug 25, 2026 | Stock Option Award |
| David L. Mahoney Director | Aug 18, 2026 | 103,606 | $12.16M | Aug 18, 2026 | OPEN MARKET PURCHASES AQCUIRED BETWEEN: 5/22/20 - 4/12/24 |
| Gary Charles Robb Officer | Aug 17, 2026 | 10,000 | $1.16M | Aug 17, 2026 | Owned Shares |
| William Guyer Officer | Aug 4, 2026 | 20,000 | $2.26M | Aug 4, 2026 | Stock Option Exercise |
| Joseph Douglas Lyon Officer | Aug 3, 2026 | 1,540 | $175.81K | Aug 3, 2026 | Option Exercise |
| Atabak Mokari Officer | Jul 30, 2026 | 40,000 | $4.59M | Jul 30, 2026 | Stock Option Exercises |
| William Guyer Officer | Jul 7, 2026 | 20,000 | $1.86M | Jul 7, 2026 | Stock Option Exercise |
| David L. Mahoney Director | Jun 16, 2026 | 20,000 | $1.67M | Jun 16, 2026 | Employee Compensation |
| James N. Wilson Director | Jun 16, 2026 | 30,000 | $2.50M | Jun 16, 2026 | STOCK OPTION AWARDS |
See a number that looks wrong?